Diagnosing atypical plasma cell dyscrasias can be challenging when lesions develop outside the skeletal system. Although plasma cell neoplasms typically manifest as osteolytic lesions within bone marrow, extramedullary multiple myeloma presents as soft-tissue masses that can easily confound clinicians. Recently, an instructive case highlighted a 77-year-old male with a history of monoclonal gammopathy of undetermined significance who developed multiple bulky extraosseous soft-tissue masses. Because these lesions radiologically simulated lymphoproliferative disorders such as non-Hodgkin lymphoma, the clinical team required an extensive multi-tier evaluation. This diagnostic dilemma demonstrates why clinicians must maintain a high index of suspicion whenever patients with pre-existing plasma cell dyscrasias present with unusual mass lesions.

Clinical Progression and Pathophysiology of Extraosseous Spread

Monoclonal gammopathy of undetermined significance represents a premalignant condition that occasionally transforms into systemic plasma cell disorders. Consequently, routine surveillance remains standard practice to monitor for malignant transformation. In rare instances, clonal plasma cells acquire hematogenous dissemination capabilities and escape bone marrow microenvironment dependence. Therefore, malignant clones infiltrate soft tissues, organs, or lymphatic basins directly. This phenomenon leads to primary or secondary extraosseous tumors that behave aggressively. Moreover, the loss of adhesion molecules and altered chemokine receptor expression often drive this extramedullary migration. As a result, patients may present with rapid tumor growth and constitutional symptoms rather than classic hypercalcemia, renal dysfunction, anemia, or bone pain.

Imaging Features of Extramedullary Multiple Myeloma

Cross-sectional imaging serves as an essential tool during the initial evaluation of occult oncologic processes. However, multimodality imaging can sometimes reveal overlapping characteristics between plasma cell neoplasms and lymphoproliferative diseases. On computed tomography, soft-tissue myelomatous masses frequently show homogeneous soft-tissue attenuation, well-circumscribed borders, and variable contrast enhancement. In addition, positron emission tomography using fluorodeoxyglucose demonstrates marked metabolic uptake in these lesions, indistinguishable from high-grade lymphomas. Furthermore, whole-body magnetic resonance imaging reveals intermediate signal intensity on T1-weighted sequences and hyperintensity on T2-weighted scans. Because these bulky masses can arise near nodal stations or abdominal organs, radiologists may initially suspect diffuse large B-cell lymphoma or systemic lymphadenopathy without immediate osseous involvement clues.

Distinguishing Extraosseous Plasmacytomas from Lymphoma

Differentiating soft-tissue plasma cell dyscrasias from systemic lymphomas requires careful synthesis of laboratory, metabolic, and anatomic findings. First, clinicians should evaluate serum and urine protein electrophoresis alongside serum free light chain ratios. While aggressive lymphomas occasionally produce secondary paraproteins, significant monoclonal protein elevation strongly points toward plasma cell pathology. Next, advanced functional imaging can clarify whether underlying diffuse marrow replacement exists. Nevertheless, imaging alone cannot reliably provide a definitive answer because both entities present with bulky adenopathy, extranodal disease, and intense metabolic avidity. Therefore, multidisciplinary tumor boards must integrate biochemical profiles and radiological patterns to guide timely interventional procedures.

Histopathological and Immunohistochemical Confirmation

Because imaging tests show substantial morphological overlap, tissue biopsy remains the gold standard for achieving an accurate diagnosis. Core needle biopsy or surgical excision yields adequate tissue architecture for comprehensive immunophenotyping. On microscopic examination, clonal plasma cells exhibit eccentric nuclei, clock-face chromatin, and abundant basophilic cytoplasm. Furthermore, immunohistochemical staining plays a decisive role in resolving diagnostic ambiguity. The malignant cells strongly express CD138, CD38, and cytoplasmic light chain restriction for either kappa or lambda. Conversely, they typically lack mature B-cell markers such as CD20, PAX5, and CD45, thereby ruling out classic B-cell lymphomas. Additionally, fluorescence in situ hybridization assists in identifying high-risk cytogenetic abnormalities that guide prognosis and therapy.

Therapeutic Implications and Long-Term Management

Establishing an exact diagnosis directly impacts therapeutic decision-making and survival outcomes. Because extraosseous disease represents a biologically aggressive myeloma phenotype, prompt initiation of systemic combination therapy is mandatory. Modern induction protocols typically incorporate proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and dexamethasone. Furthermore, eligible patients should undergo autologous stem cell transplantation to consolidate clinical remission. In localized symptomatic masses causing neural compromise or severe obstruction, clinicians often incorporate targeted radiation therapy. Regular disease surveillance requires repeat serum free light chain assays and serial fluorodeoxyglucose positron emission tomography scans to detect early recurrence and guide clinical adjustments.

Frequently Asked Questions

What is extramedullary multiple myeloma and how frequently does it occur?

Extramedullary disease involves plasma cell proliferation outside the skeletal marrow environment, affecting organs, lymph nodes, or soft tissues. It occurs in roughly six to eight percent of newly diagnosed myeloma patients and up to twenty percent during disease relapse. This manifestation typically reflects an aggressive biological phenotype requiring intensive systemic therapy.

Why does soft-tissue myeloma frequently simulate systemic lymphoma on imaging?

Both entities present on imaging as bulky, homogeneous soft-tissue masses with variable contrast enhancement and intense metabolic uptake on positron emission tomography. Furthermore, myelomatous deposits frequently involve lymph node basins and retroperitoneal spaces without adjacent bone erosion, closely mimicking primary nodal and extranodal lymphomas.

Which diagnostic tests are most critical to confirm extraosseous plasma cell neoplasms?

A definitive diagnosis requires a core needle biopsy with immunohistochemical staining for CD138, CD38, and light chain restriction to differentiate plasma cells from lymphoma. Additionally, clinicians must correlate histopathology with serum free light chain assays, protein electrophoresis, and whole-body functional imaging.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Salvador-Sáenz P et al. Extramedullary multiple myeloma simulating lymphoproliferative disease on multimodality imaging. Jpn J Clin Oncol. 2026 Aug 16. doi: undefined. PMID: 42604594.
2. Cho R, Myers DT, Onwubiko IN, Williams TR. Extraosseous multiple myeloma: imaging spectrum in the abdomen and pelvis. Abdom Radiol (NY). 2021 Mar;46(3):1194-1209.
3. Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017 Apr;18(4):e206-e217.
4. Bharti A, Kumar N, Sharma S. Extramedullary manifestation of plasma cell dyscrasias: diagnostic challenges and clinical outcomes. Indian J Hematol Blood Transfus. 2022;38(2):215-223.